Whalegun
List

Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing

USTR noticeTrade dealPublished 04/02Open the original

Summary

USTR, HHS and Commerce announce a U.S.-UK arrangement on pharmaceutical pricing, which they say addresses long-standing imbalances in pharmaceutical trade and improves access to medicines in the United Kingdom.

By industry

Day by day after the announcement

Healthcare & Drug Pricing stocks and the S&P 500 after the announcement, cumulative %
Healthcare & Drug Pricing stocks and the S&P 500 after the announcement, cumulative %
DayHealthcare & Drug Pricing stocksS&P 500
26/04/010.0%0.0%
26/04/02−0.2%+0.1%
26/04/06+1.0%+0.6%
26/04/07−0.0%+2.9%
26/04/08+1.6%+3.0%
26/04/09+1.8%+3.7%
26/04/10+0.6%+3.8%
26/04/13+0.6%+4.8%
26/04/14+0.7%+6.0%
26/04/15−0.3%+6.8%
26/04/16+0.3%+7.1%
26/04/17+1.4%+8.4%
26/04/20+0.4%+8.3%
26/04/21−0.1%+7.9%
26/04/22−0.6%+8.4%
26/04/23+0.7%+8.3%
26/04/24−0.5%+8.9%
26/04/27−0.6%+9.3%
26/04/28+0.5%+8.7%
26/04/29+1.1%+8.8%
26/04/30+2.0%+9.9%

Korean stocks in these industries

  • Samsung Biologics 207940
  • Celltrion 068270
  • SK Biopharmaceuticals 326030

Trades in these industries around the announcement

Members' and insiders' trades in the industries' stocks, 30 days before to 30 days after.

  • Steven H. Collis

    BuyElevance Health

    $869.5K

    Filed 03/06

  • Alan Armstrong

    Full saleAmgen

    $15K–$50K

    Reported 07/21

  • Alan Armstrong

    BuyUnitedhealth Group

    $15K–$50K

    Reported 07/21

  • Alan Armstrong

    Full salePfizer

    $50K–$100K

    Reported 07/21

  • Alan Armstrong

    BuyAbbVie

    $15K–$50K

    Reported 07/21

  • Alan Armstrong

    BuyJohnson & Johnson

    $15K–$50K

    Reported 07/21

  • Alan Armstrong

    Full saleMerck

    $15K–$50K

    Reported 07/21

  • Alan Armstrong

    BuyElevance Health

    $1K–$15K

    Reported 07/21

  • Alan Armstrong

    BuyMcKesson

    $1K–$15K

    Reported 07/21

  • Alan Armstrong

    BuyJohnson & Johnson

    $1K–$15K

    Reported 07/21

  • Alan Armstrong

    BuyGilead Sciences

    $1K–$15K

    Reported 07/21

  • Alan Armstrong

    Full saleELI Lilly

    $1K–$15K

    Reported 07/21

  • Patrick Hugh Conway

    SellUnitedhealth Group

    $284K

    Filed 04/27

  • David V. Elkins

    SellBristol Myers Squibb

    $1.6M

    Filed 04/02

  • Daniel Patrick O'Day

    Sell10b5-1 planGilead Sciences

    $1.4M

    Filed 03/30

  • David Ryan Purdue

    SellAbbVie

    $1.2M

    Filed 03/06

  • Daniel Patrick O'Day

    Sell10b5-1 planGilead Sciences

    $895.1K

    Filed 04/29

  • Andrew D. Dickinson

    Sell10b5-1 planGilead Sciences

    $432.7K

    Filed 03/17

  • Andrew D. Dickinson

    Sell10b5-1 planGilead Sciences

    $422.9K

    Filed 04/16

  • Daniel Patrick O'Day

    Sell10b5-1 planGilead Sciences

    $396.5K

    Filed 04/29

Successful Conclusion of the United States–United Kingdom Arrangement on Pharmaceutical Pricing | Whalegun